JP2010536837A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536837A5
JP2010536837A5 JP2010521478A JP2010521478A JP2010536837A5 JP 2010536837 A5 JP2010536837 A5 JP 2010536837A5 JP 2010521478 A JP2010521478 A JP 2010521478A JP 2010521478 A JP2010521478 A JP 2010521478A JP 2010536837 A5 JP2010536837 A5 JP 2010536837A5
Authority
JP
Japan
Prior art keywords
taxane
composition according
pvp
composition
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521478A
Other languages
English (en)
Japanese (ja)
Other versions
JP5404625B2 (ja
JP2010536837A (ja
Filing date
Publication date
Priority claimed from GB0716591A external-priority patent/GB0716591D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Publication of JP2010536837A publication Critical patent/JP2010536837A/ja
Publication of JP2010536837A5 publication Critical patent/JP2010536837A5/ja
Application granted granted Critical
Publication of JP5404625B2 publication Critical patent/JP5404625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521478A 2007-08-24 2008-08-22 組成物 Active JP5404625B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
US60/957,764 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
GB0716591.3 2007-08-24
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (3)

Publication Number Publication Date
JP2010536837A JP2010536837A (ja) 2010-12-02
JP2010536837A5 true JP2010536837A5 (enExample) 2012-10-18
JP5404625B2 JP5404625B2 (ja) 2014-02-05

Family

ID=38599259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521478A Active JP5404625B2 (ja) 2007-08-24 2008-08-22 組成物

Country Status (5)

Country Link
JP (1) JP5404625B2 (enExample)
CN (1) CN101854919B (enExample)
ES (1) ES2535401T3 (enExample)
GB (1) GB0716591D0 (enExample)
RU (1) RU2488384C2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
CN111465389B (zh) 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
CN113473982A (zh) * 2018-12-21 2021-10-01 莫德拉药物股份有限责任公司 使用多西他赛和cyp3a抑制剂组合治疗实体瘤
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1048956B (zh) * 1999-05-27 2006-07-28 阿库斯菲尔公司 多孔药物基质及其制造方法
EP1539111A1 (en) * 2002-08-05 2005-06-15 DSM IP Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Similar Documents

Publication Publication Date Title
US20230138361A1 (en) Enhanced delivery epinephrine compositions
JP2010536837A5 (enExample)
JP2011037876A5 (enExample)
US20170290776A1 (en) Pharmaceutical compositions with enhanced permeation
JP2009530415A5 (enExample)
EP3085357A1 (en) Microneedle
JP2010510241A5 (enExample)
US12433850B2 (en) Enhanced delivery epinephrine and prodrug compositions
JP2024012484A (ja) 増強された透過を有する医薬組成物
RU2488384C2 (ru) Композиции для лечения неопластических заболеваний
CN103705494A (zh) 一种胰岛素纳米透皮贴剂及其制备方法
IL313551A (en) Enhanced delivery epinephrine and prodrug compositions
CN104352482A (zh) 膜组合物
US11273131B2 (en) Pharmaceutical compositions with enhanced permeation
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
US20190022022A1 (en) Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) Enhanced delivery epinephrine compositions
JP2012500788A5 (enExample)
RU2012101817A (ru) Композиции олмесартана медоксомила в форме наночастиц, способ их получения и содержащие их фармацевтические композиции
US20180125977A1 (en) Enhanced delivery epinephrine compositions
JP2011509925A (ja) タキサン誘導体を含有する、改良された再構成時間を有する凍結乾燥医薬組成物及びその製法
JP2006524190A5 (enExample)
US20250108017A1 (en) Enhanced delivery epinephrine and prodrug compositions
CN107427462B (zh) 固态分散体
US11260024B2 (en) Polymeric compositions containing ambient-temperature stable biopharmaceuticals and methods for formulation thereof